Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy: final 48-week clinical and virologic outcomes. - Test2 - elhamkhani - TriplyDB

Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy: final 48-week clinical and virologic outcomes.

Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy: final 48-week clinical and virologic outcomes.

http://www.wikidata.org/entity/Q37189025

about

New tools for quantifying HIV-1 reservoirs: plasma RNA single copy assays and beyond Moving away from Ritonavir, Abacavir, Tenofovir, and Efavirenz (RATE)--agents that concern prescribers and patients: a feasibility study and call for a trial Baseline natural killer and T cell populations correlation with virologic outcome after regimen simplification to atazanavir/ritonavir alone (ACTG 5201).Long-acting nanoformulated antiretroviral therapy elicits potent antiretroviral and neuroprotective responses in HIV-1-infected humanized mice.Detection of HIV-1 at between 20 and 49 copies per milliliter by the Cobas TaqMan HIV-1 v2.0 assay is associated with higher pretherapy viral load and less time on antiretroviral therapy.Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy Protease inhibitor monotherapy is associated with a higher level of monocyte activation, bacterial translocation and inflammation.Atazanavir/ritonavir-based combination antiretroviral therapy for treatment of HIV-1 infection in adults.Treatment simplification in HIV-infected adults as a strategy to prevent toxicity, improve adherence, quality of life and decrease healthcare costs.Single genome sequencing of HIV-1 gag and protease resistance mutations at virologic failure during the OK04 trial of simplified versus standard maintenance therapy Clinical management of HIV drug resistance.HIV-1 amino acid changes among participants with virologic failure: associations with first-line efavirenz or atazanavir plus ritonavir and disease status.Modifying Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected Patients.Therapeutic Vaccination With Dendritic Cells Loaded With Autologous HIV Type 1-Infected Apoptotic Cells.Using cost as a consideration for antiretroviral regimen selection: an example using average wholesale prices Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy.The CASTLE study: atazanavir/r versus lopinavir/r in antiretroviral-naive patients.Switch strategies in antiretroviral therapy regimens.HIV protease inhibitors: present and future

P2860

Q27027164-C8AAC970-A3F2-408A-91C0-936F268545F2 Q28540037-BC54639C-6979-401B-A4FC-A534AD7B0943 Q33572705-AFCF99C8-DA42-421E-AD15-E7D9D7DEFA19 Q33625213-F5A0796E-3B9B-4763-AD76-231C76DA5B8C Q33827131-3415D1E7-D300-4934-ABBF-E6F61CB1E138 Q33962223-CA48F395-620B-44B3-9203-B9E5A04E8478 Q34288534-6FDA8D0B-C09A-4EF9-ABE3-163F60F67E1D Q35079510-05BC2BDF-F6B7-468B-9242-138AA7FC6914 Q35147189-DD16E2BA-D064-4328-B61A-057A3F1D0DFF Q35158051-F1756E3B-9AF4-410E-AB58-CDFB276C007B Q35261045-9075F4E4-7153-4631-BB4B-186B5F0F8953 Q36412256-BD6129E9-AA1A-4DC2-82EC-3CF873AA9A6C Q36426953-3CD8BE33-EDB3-48C9-A650-B1878AA17EEC Q36745227-74389E9D-840A-4D4C-A16B-1267BBFF9227 Q36981298-76695F21-658C-4B2A-AD94-A46B4C27D57A Q37200979-04C4102C-2EFA-42FC-801E-4D2A49C2813E Q37593100-1C831911-16E7-4BBF-82FD-EE206D6A1A4B Q38235295-09527500-887C-4D6A-AF9F-AC60CCBDDADD Q58290794-B29E536B-FEFA-47B6-9D89-D091CCBB9ADF

P2860

Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy: final 48-week clinical and virologic outcomes.

http://www.wikidata.org/entity/Q37189025

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on March 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Regimen simplification to ataz ...... inical and virologic outcomes.

@en

Regimen simplification to ataz ...... inical and virologic outcomes.

@nl

type

label

Regimen simplification to ataz ...... inical and virologic outcomes.

@en

Regimen simplification to ataz ...... inical and virologic outcomes.

@nl

prefLabel

Regimen simplification to ataz ...... inical and virologic outcomes.

@en

Regimen simplification to ataz ...... inical and virologic outcomes.

@nl

P1433

Q37189025-ACCA965B-75C9-4DF9-8704-C3179CA117A6

P1476

Q37189025-D3F6F9A6-1DAA-4BF8-9E7B-FEC51EAC168A

P2093

Q37189025-0D8F7820-8C74-4E08-A5AF-E3CEB4C9D11C

Q37189025-18AB9603-7C41-4BCB-838E-533E709137E2

Q37189025-24FBE619-6576-4641-AF77-79A1A4C084B8

Q37189025-28A17DE2-257E-4891-AB99-FFF08BF69109

Q37189025-2A5EC51E-156B-44EF-B791-3A7BE1AD4706

Q37189025-2B50E1B7-35FA-4406-B405-FBDD6330D20A

Q37189025-2C2D2071-1035-4059-84E4-52FA35E8C113

Q37189025-31820D22-22E5-4E5B-89CA-737137C02B11

Q37189025-3A72E78F-DC6B-4FC7-9D7B-893AD6A42C8A

Q37189025-53525AF2-A1CC-4A3E-BBA0-A1E1DFEEE9FF

P2860

Q37189025-0BFC06C7-DE9A-412A-B64D-61D749A4BA5C

Q37189025-1259BF27-6435-43D7-91B8-003EDC12BC8A

Q37189025-27AA0927-84BB-45F7-B575-A5E64FA81371

Q37189025-2AAF5128-89C8-4B4B-95C8-9CEB42257D56

Q37189025-44A43743-0A61-42B5-A91C-AE8529B6EC0D

Q37189025-710113CA-92BB-49A4-8786-F92025C68F9B

Q37189025-7DBEF359-8A0B-4012-9062-78D907289453

Q37189025-82DF626A-9E2F-4FED-9AD8-39CD130AACD6

Q37189025-99445056-768B-40E9-A8AB-F5798A1D9468

Q37189025-A0530B42-5A10-44F7-9CDE-2EA661FF7543

P304

Q37189025-92744DC7-689D-4216-B218-836D0C9F134A

P31

Q37189025-9D9B50B3-B109-4D31-839F-1931CCCA6073

P356

Q37189025-18ED07BC-911D-46A1-892B-B9BACDD2358A

P407

Q37189025-2098CD5D-DB57-4FDF-A649-3C723B10CE31

P433

Q37189025-48A976B8-1F5D-41CB-9AC1-41C76C361E0A

P478

Q37189025-73CCB5FA-DEC6-45AB-BAD0-BF2E33E074C8

P50

Q37189025-645139DB-5010-4DF9-9B9B-3BD8A5BD0A63

Q37189025-8BA0679E-051B-4A81-8638-02BFAB34D64B

P577

Q37189025-693BFAD2-860E-4ED2-B498-47F9C53FDA5C

P5875

Q37189025-317875C8-D6FA-43E0-9C84-299B8AEAED43

P698

Q37189025-1E7651D7-2F0B-4148-A385-CCA5196AB4C2

P921

Q37189025-9C668EBD-7FC0-41C6-ABAB-B13FE3BDC872

Q37189025-EB582709-24F8-43B9-B35B-1F1EBA77AEA9

P932

Q37189025-12B66319-80A6-43C2-B556-5DC8968356F7

P356

P1433

The Journal of Infectious Diseases

P1476

Regimen simplification to ataz ...... inical and virologic outcomes.

@en

P2093

A Gregory DiRienzo

http://www.w3.org/2001/XMLSchema#string

Ann Wiegand

http://www.w3.org/2001/XMLSchema#string

Barbara Bastow

http://www.w3.org/2001/XMLSchema#string

Catherine Godfrey

http://www.w3.org/2001/XMLSchema#string

Courtney V Fletcher

http://www.w3.org/2001/XMLSchema#string

Frank Maldarelli

http://www.w3.org/2001/XMLSchema#string

Gary Thal

http://www.w3.org/2001/XMLSchema#string

John E McKinnon

http://www.w3.org/2001/XMLSchema#string

John M Coffin

http://www.w3.org/2001/XMLSchema#string

John W Mellors

http://www.w3.org/2001/XMLSchema#string

P2860

Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis.

Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection.

Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy.

Potential risks and benefits of HIV treatment simplification: a simulation model of a proposed clinical trial

New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma.

Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression.

Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial.

A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy.

Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AAC

Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results.

P304

866-871

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1086/597119

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

199

http://www.w3.org/2001/XMLSchema#string

P50

David M. Margolis

Susan Swindells

P577

2009-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23975822

http://www.w3.org/2001/XMLSchema#string

P698

19191590

http://www.w3.org/2001/XMLSchema#string

P921

antiretroviral drug

P932

2680942

http://www.w3.org/2001/XMLSchema#string